Novo Nordisk Adjusts 2025 Projections After Wegovy Sales Disappoint
Novo Nordisk, the Danish pharmaceutical giant, has lowered its long-term sales forecast for 2025 due to weaker-than-expected performance of its blockbuster weight-loss drug Wegovy. Despite the setback, the company reported a robust first-quarter profit that exceeded analyst expectations, sparking discussions about its future growth strategies in the competitive obesity drug market.
Mixed Results: Wegovy’s Decline vs. Strong Quarterly Earnings
The company revealed that Wegovy, its highly anticipated GLP-1 receptor agonist for chronic weight management, generated $336 million in Q1 2024—a figure that fell 18% short of Wall Street projections. This unexpected dip comes just 18 months after the drug’s high-profile U.S. launch, which had initially driven Novo Nordisk’s market capitalization past $500 billion.
However, the quarterly financial report contained silver linings:
- Overall operating profit rose 31% to $3.2 billion
- Diabetes drug Ozempic saw sales jump 45% year-over-year
- Total revenue increased by 24% to $7.8 billion
“The Wegovy numbers certainly raise eyebrows, but we’re seeing phenomenal performance across our broader portfolio,” said Lars Fruergaard Jørgensen, Novo Nordisk’s CEO, in an earnings call. “This isn’t a story of decline—it’s a story of rebalancing.”
Market Forces Behind Wegovy’s Underperformance
Analysts point to three key factors contributing to Wegovy’s sales slump:
- Supply chain limitations that restricted patient access in key markets
- Increased competition from Eli Lilly’s rival drug Zepbound
- Changing insurance coverage policies for weight-loss medications
Dr. Sarah Williamson, a pharmaceutical analyst at Bernstein Research, notes: “The supply issues created a perfect storm. Novo couldn’t manufacture enough starter doses to meet demand, which pushed many patients toward alternatives. When you combine that with Lilly’s aggressive marketing for Zepbound, you get this surprising reversal.”
Market share data supports this analysis:
- Wegovy’s U.S. new prescription volume declined 22% QoQ
- Zepbound captured 38% of new weight-loss drug prescriptions in March
- Only 47% of U.S. health plans now cover Wegovy, down from 52% in 2023
Strategic Shifts in Novo Nordisk’s Growth Plans
In response to these challenges, the company has revised its 2025 sales growth projection from 15-19% down to 10-14%. However, executives emphasized this reflects a strategic recalibration rather than diminished confidence in their pipeline.
Doubling Down on Diabetes and New Indications
Novo Nordisk appears to be pivoting resources toward two key areas:
1. Expanding Ozempic’s market dominance: The diabetes medication, which uses the same active ingredient as Wegovy (semaglutide), continues to show strong growth potential. The company recently received FDA approval for Ozempic’s use in reducing cardiovascular risk—a move that could open access to 16 million additional U.S. patients.
2. Developing next-generation therapies: The pharmaceutical firm has accelerated trials for CagriSema, a novel combination treatment showing 24% greater weight loss than Wegovy in phase 2 trials. They’ve also increased R&D spending by 29% year-over-year to $1.4 billion.
“We’re playing both the short game and long game simultaneously,” explained Chief Scientific Officer Martin Holst Lange. “While we optimize our current GLP-1 portfolio, we’re building the foundation for sustained leadership in metabolic diseases.”
Investor Reactions and Market Implications
The mixed news created volatility in Novo Nordisk’s stock (NVO):
- Shares dropped 6.2% on the Wegovy guidance revision
- Recovered 3.8% after analysts digested the strong earnings beat
- Currently trading at 32 times earnings—a premium to most pharma peers
Goldman Sachs maintained its “Buy” rating but lowered its price target from $145 to $132, citing “near-term headwinds but intact long-term growth drivers.” Meanwhile, JPMorgan downgraded the stock to “Neutral,” warning that “the obesity drug market may be segmenting faster than anticipated.”
The Road Ahead for Weight-Loss Therapeutics
Industry experts suggest Novo Nordisk’s experience reflects broader trends in the rapidly evolving anti-obesity medication market. With global sales projected to reach $100 billion by 2030, competition is intensifying on multiple fronts:
- Oral formulations: Both Novo and Lilly are developing pill versions of their injectable drugs
- Combination therapies: Next-gen drugs targeting multiple metabolic pathways
- Prevention approaches: Earlier intervention in pre-obesity patients
“This isn’t just about who has the most effective drug anymore,” notes Dr. Robert Kushner, an obesity specialist at Northwestern University. “It’s about who can deliver sustainable weight management solutions with the best access, tolerability, and long-term outcomes.”
For patients and investors alike, the coming months will prove critical as Novo Nordisk addresses its supply chain challenges and positions its expanded portfolio. The company plans to open two new production facilities in Denmark and the U.S. by late 2024, which could alleviate the dose shortages that hampered Wegovy’s rollout.
As the metabolic medicine landscape continues to shift, one thing remains clear: The race to treat obesity and diabetes has become pharma’s most dynamic—and unpredictable—growth frontier. Watch this space for ongoing coverage of Novo Nordisk’s strategic moves and the evolving weight-loss drug market.
See more Business Focus Insider Team
